Dangerous Drug: Sitagliptin Phosphate(sit ah glip’ ten)
Januvia
PREGNANCY CATEGORY B
Drug Classes
Antidiabetic drug
DPP-4 (dipeptidyl peptidase-4) enzyme inhibitor
Therapeutic Actions
Slows the inactivation of the incretin hormones, increasing these hormone levels and prolonging their activity. The incretin hormones stimulate insulin release in response to a meal and help to regulate glucose homeostasis throughout the day. This increases and prolongs insulin release and reduces hepatic glucose production to help achieve glycemic control.
Indications
Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus, as monotherapy or with other oral antidiabetics
Contraindications and Cautions
Contraindicated with history of serious hypersensitivity reactions to sitagliptin, type 1 diabetes, diabetic ketoacidosis.
Use cautiously with renal insufficiency, concurrent use of other drugs known to cause hypoglycemia, pregnancy, lactation.
Available Forms
Tablets—25, 50, 100 mg
Dosages
Adults
100 mg/day PO as monotherapy or combined with metformin, pioglitazone, rosiglitazone, or other oral drugs.
Pediatric patients
Safety and efficacy not established.
Patients with renal impairment
With CrCl of 30–50 mL/min, 50 mg/day PO; with CrCl less than 30 mL/min, 25 mg/day PO.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
